Stock Analiz

MRK vs NVS stock comparison

Merck & Co. vs. Novartis · data as of November 13, 2026

Merck & Co. (MRK) has a market value of about $364.3B, Novartis (NVS) about $306.3B. Over their latest twelve months Merck & Co. had revenue of $67.4B and Novartis $57.4B.

On our five checks Merck & Co. scores higher: 2.8 out of 5 (average) against 2.0 (weak).

By area, the stronger company is Merck & Co. on future growth; Merck & Co. on track record; Novartis on financial health; Merck & Co. on shareholder returns.

Novartis is cheaper on earnings (P/E 30.7 vs. 150.8), while Merck & Co. grew revenue faster over five years (9.4% vs. 2.3% a year).

Merck & Co. leads on 9 of the compared lines and Novartis on 15.

Side by side

MRKNVS
Size and price
Market cap$364.3B$306.3B
Share price$147.76$160.50
Score
Overall score (of 5)2.82.0
Value00
Future growth20
Track record54
Financial health23
Shareholder returns53
Valuation
P/E (TTM)150.830.7
Forward P/E17.617.0
Price / free cash flow24.721.9
Price / sales5.45.3
EV / EBITDA32.514.4
PEG7.102.02
DCF value vs. price−31%−9%
Business
Revenue$67.4B$57.4B
Net income$2.5B$10.0B
Free cash flow$14.7B$14.0B
Net margin3.6%17.5%
Gross margin (5-yr avg.)73.4%76.4%
ROIC (5-yr avg.)16.3%14.1%
Growth
Revenue growth (1 yr)1.3%8.4%
Revenue growth (5 yrs, per year)9.4%2.3%
EPS growth (5 yrs, per year)21.2%15.2%
Balance sheet and payouts
Net cash (cash minus debt)-$44.1B-$39.3B
Dividend yield2.30%2.95%
Shareholder yield3.7%6.0%
Analysts
Upside to average target+9%−2%
Consensus ratingBuyHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: MRK TTM to September 30, 2026, NVS TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Merck & Co. or Novartis?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Merck & Co. scores 2.8 out of 5 and Novartis 2.0; the table shows where each one is stronger.

Is Merck & Co. cheaper than Novartis?

On trailing earnings, Novartis trades at a P/E of 30.7 and Merck & Co. at 150.8, so Novartis is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Merck & Co. or Novartis?

Over five years Merck & Co. grew revenue about 9.4% a year and Novartis about 2.3% a year.

Which pays a higher dividend?

Merck & Co. yields 2.30% and Novartis 2.95%.

Full Merck & Co. analysis → Full Novartis analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.